Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study.

ABSTRACT:

Aims

Type 2 diabetes (T2D) is a heterogeneous disease, with varying pathogenetic mechanisms influencing treatment response. Glucagon-like peptide-1 receptor agonists (GLP-1RA) offer clear metabolic benefits in T2D, but interindividual variability in response is observed. This retrospective study investigated whether GLP-1RA effectiveness varies by T2D phenotypes (severe insulin-deficient diabetes [SIDD], severe insulin-resistant diabetes [SIRD], mild obesity-related diabetes [MOD], mild age-related diabetes [MARD]) and assessed predictors of HbA1c reduction.

Materials and methods

Individuals attending the Endocrinology Unit at the University Hospital Policlinico Consorziale in Bari, Italy, between 01 January 2014, and 31 August 2024, were evaluated for participation. T2D phe

SUBMITTER: Caruso I 

PROVIDER: S-EPMC12515759 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature